Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Mochida to Prevail through R&D, Alliance, Emphasis on Results
February 12, 2001
- Keisansho to Promote Healthcare Services as Industry
February 12, 2001
- REGULATORY NEWS IN BRIEF -2-
February 12, 2001
- Dainippon to Withdraw Aleviatin Fine Granules
February 12, 2001
- Drug Makers Must Assume Full Responsibility for Their Products
February 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 12, 2001
- Bayer Yakuhin, Meiji Seika to Comarket Ciproxan
February 12, 2001
- Japan Not to Introduce Inactivated Vaccine against Polio
February 12, 2001
- Combination Therapy with Protopic, Steroid Reported: Fujisawa Seminar
February 12, 2001
- Kyorin Establishes Subsidiary to Gain Foothold in US Market
February 12, 2001
- Serious ADR Reported for Sarpogrelate
February 12, 2001
- Daiichi Starts Drug Discovery Research in New Laboratory
February 12, 2001
- Kirin Brewery Wins Epoetin Patent Suit Against Snow Brand Milk
February 12, 2001
- Typographical Error Found in NHI Price of Lorcam Presented to Chuikyo
February 12, 2001
- Non-compliance with GCP Found in 1,529 Cases in 3-year Survey
February 12, 2001
- Fukujin Ties Up with Inagaki Yakuhin
February 12, 2001
- OTC NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -1-
February 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 12, 2001
- BUSINESS NEWS IN BRIEF -2-
February 12, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…